AORT

Artivion, Inc.

21.82 USD

Last updated Oct 13, 01:18 UTC

Yesterday HIGH

$21.6

Yesterday LOW

$20.21

52w HIGH

$48.25

52w LOW

$19.16

EPS

0.13

PE

167.85

Next Earnings

Nov 5, 2026

Overview News Government Trades Fundamentals

Artivion, Inc. stock is down -13% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 38.24% of the previous 33 October’s closed higher than September.

Benzinga Newsdesk

Fri May 8, 2026

Artivion shares are trading lower after the company reported Q1 financial results and cut its FY26 sales guidance with its midpoint below estimates.
Benzinga Insights

Fri May 8, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Newsdesk

Fri May 8, 2026

Needham Maintains Buy on Artivion, Lowers Price Target to $44

Needham analyst Mike Matson maintains Artivion (NYSE:AORT) with a Buy and lowers the price target from $58 to $44.
Benzinga Newsdesk

Thu May 7, 2026

Artivion shares are trading lower after the company reported Q1 financial results and cut its FY26 sales guidance with its midpoint below estimates.
Benzinga Insights

Thu May 7, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Newsdesk

Thu May 7, 2026

Artivion Lowers FY2026 Sales Guidance from $486.000M-$504.000M to $480.000M-$496.000M vs $495.284M Est

Artivion (NYSE:AORT) lowers FY2026 sales outlook from $486.000 million-$504.000 million to $480.000 million-$496.000 million vs $495.284 million estimate.
Benzinga Newsdesk

Thu May 7, 2026

Artivion Q1 Adj. EPS $0.08 Beats $0.05 Estimate, Sales $116.337M Beat $115.803M Estimate

Artivion (NYSE:AORT) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.05 by 60 percent. This is a 33.33 percent increase over earnings of $0.06 per share from the same period
Benzinga Newsdesk

Tue Apr 7, 2026

Needham Reiterates Buy on Artivion, Maintains $58 Price Target

Needham analyst Mike Matson reiterates Artivion (NYSE:AORT) with a Buy and maintains $58 price target.
Avi Kapoor

Tue Apr 7, 2026

UnitedHealth, Alignment Healthcare, Humana And Other Big Stocks Moving Higher On Tuesday

Dow Jones falls 250 points as UnitedHealth Group rises on Medicare reimbursement boost, other stocks also see gains in today's session.
Benzinga Newsdesk

Tue Apr 7, 2026

The FDA Approves Premarket Approval Application For NEXUS Aortic Arch System, Developed By Artivion's Partner; The Approval Entitles Artivion To Exercise Its Option To Acquire Endospan At Any Time Within 90 Days

Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA)

QQQ $744.01 USD

JPM $334.62 USD

MRVL $265.90 USD

SOXL $126.84 USD

CVNA $59.41 USD

SKHY SKHY $162.27 USD

BMNR $23.84 USD

WULF $13.37 USD

CRWV $80.24 USD

CBRS $146.66 USD